Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/kawasaki-disease/descriptif_3897734
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3897734

Kawasaki Disease, Softcover reprint of the original 1st ed. 2017 Current Understanding of the Mechanism and Evidence-Based Treatment

Langue : Anglais

Coordonnateurs : Saji Ben Tsutomu, Newburger Jane W., Burns Jane C., Takahashi Masato

Couverture de l’ouvrage Kawasaki Disease

This book provides the most up-to-date information on the clinical research into and medical management of Kawasaki Disease, and opens the door for new pathological insights. Its nearly 50 sections cover basic research, genetic backgrounds, bacterial and?biological?evidence, and medical?treatment?with?intravenous?immunoglobulin, steroids, and recent anti-cytokine approaches. It offers an invaluable resource for general pediatricians, pediatric and adult cardiologists, pediatric cardiac surgeons, infectious disease specialists, pediatric rheumatologists, epidemiologists, and basic researchers in these disciplines.

Part I: Basic Research.- 1 The History of Kawasaki Disease: A Personal Perspective.- 2 Histopathology of coronary arteritis in acute Kawasaki disease and murine systemic vasculitis induced by Candida albicans cell wall polysaccharide.- 3Histopathological characteristics aspects of organs other than the heart of noncardiac organs in Kawasaki disease.- 4 Identification of Novel Kawasaki Disease Susceptibility Genes by Genome-Wide Association Studies.- 5 Immunological Abnormalities and Use of Biomarkers and Cytokines to Predict the Severity of Kawasaki Disease.- 6 Pathophysiology of Kawasaki Disease.- 7 Update on Pathogenesis: Lessons Learned from Animal Models of Disease.- 8 The climate–KD link.- 9 Kawasaki Disease Shock Syndrome.- 10 Future directions in Kawasaki disease research.- Part II: Epidemiology.- 11 Epidemiologic Perspectives.- 12 Update on nationwide surveys and epidemiologic characteristics of Kawasaki disease in Japan.- 13 Kawasaki Disease Epidemiology in Europe.- 14 Recent topics in the epidemiology of Kawasaki disease.- Part III: Diagnosis and Examinations.- 15 Overview of Medical Treatment.- 16 Overview of the New Japanese Guideline2012 for the Medical Treatment of Acute Stage of Kawasaki Disease.- 17 Tumor Necrosis Factor-α Blockade for Treatment of Acute Kawasaki Disease.- 18 Methylprednisolone Pulse Therapy for Nonresponders to Immunoglobulin Therapy.- 19 Prednisolone.- 20 Cyclosporin A for IVIG nonresponders.- 21 Other challenging therapies.- 22 Antiplatelet and Antithrombotic Therapy for Giant Coronary Aneurysm.- 23 Characteristics of Sudden Cardiac Death Late After Acute Kawasaki Disease.- 24 Kawasaki disease diagnosis and complication rates in the United States and Japan.- 25 Mechanism of Action of Immunoglobulin: Sialylated IgG.- 26 Treatment Options for Refractory Kawasaki Disease: Alternative Treatments for Infliximab Nonresponders.- 27 Ulinastatin.- 28 Diagnosis and Management of Cardiovascular Risk Factors.- 29 Diagnosis and Characteristics of Typical and Incomplete Kawasaki Disease.- 30 Scoring systems to predict coronary artery lesions and nonresponse to initial intravenous immunoglobulin therapy.- 31 Use of magnetic resonance angiography for assessment of coronary artery lesions caused by Kawasaki disease.- 32 CT coronary and myocardial images in patients with coronary artery lesions.- 33 Long-Term Follow-up and Education Regarding Daily Life Activities, School Life, and Guidelines After Acute KD.- 34 Assessment of cardiac ischemia during acute and long-term follow-up and rheologic assessment of coronary artery lesions after Kawasaki disease.- 35 Promising biomarkers in acute Kawasaki disease and acute coronary ischemia.- 36 Coronary artery diameter Z score calculator.- 37 Evidence of endothelial damage in acute KD.- 38 Oxidative Stress in Kawasaki Disease.- Part V: Catheter Intervention and Surgery.- 39 Antiplatelet and anticoagulant therapies for Kawasaki disease: theory and practice.- 40 Guidelines for catheter intervention for coronary artery lesions in Kawasaki disease.- 41 Long-term Clinical Follow-up After Rotational Atherectomy for Coronary Arterial Stenosis in Kawasaki Disease.- 42 Long-term outcomes of pediatric coronary artery bypass grafting and downsizing for giant coronary aneurysms.- 43 Long-term outcomes of pediatric coronary artery bypass grafting and downsizing for giant coronary aneurysms.- Part VI: Follow-up Concerns.- 44 Functional and structural alterations of coronary arteries late after Kawasaki disease and the risk of acute coronary syndrome in adults.- 45 Psychosocial Effects of Kawasaki Disease and Transition to Adult Care.- 46 Kawasaki Disease: Road Map for the Future.- Appendix: Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013).

Dr. Ben Tsutomu Saji, First Department of Pediatrics, Toho University Omori Medical Center, Tokyo, Japan. 

Dr. Jane W. Newburger, Harvard Medical School, Department of Cardiology, Boston Children's Hospital, Boston, USA

Dr. Jane C. Burns, Department of Pediatrics, Rady Children’s Hospital, University of California San Diego School of Medicine, La Jolla, USA

Dr. Masato Takahashi, Heart Center, Seattle Children's Hospital, Seattle, USA

Covers all essential information for clinicians, including basic science and practical treatment

Discusses the latest advances using anti-cytokine therapies

Compiled by an international team of experts

Date de parution :

Ouvrage de 552 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 137,14 €

Ajouter au panier

Date de parution :

Ouvrage de 552 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

Prix indicatif 189,89 €

Ajouter au panier